MA51672A - Composés destinés au traitement des troubles kinases-dépendants - Google Patents
Composés destinés au traitement des troubles kinases-dépendantsInfo
- Publication number
- MA51672A MA51672A MA051672A MA51672A MA51672A MA 51672 A MA51672 A MA 51672A MA 051672 A MA051672 A MA 051672A MA 51672 A MA51672 A MA 51672A MA 51672 A MA51672 A MA 51672A
- Authority
- MA
- Morocco
- Prior art keywords
- kinasis
- treatment
- compounds intended
- dependent disorders
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| US201862622629P | 2018-01-26 | 2018-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51672A true MA51672A (fr) | 2020-12-02 |
Family
ID=65409542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051672A MA51672A (fr) | 2018-01-26 | 2019-01-25 | Composés destinés au traitement des troubles kinases-dépendants |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (fr) |
| EP (1) | EP3743068A1 (fr) |
| JP (2) | JP7307733B2 (fr) |
| KR (1) | KR20200124678A (fr) |
| AU (1) | AU2019212719A1 (fr) |
| BR (1) | BR112020015199A2 (fr) |
| CA (1) | CA3088127A1 (fr) |
| CL (1) | CL2020001930A1 (fr) |
| CO (1) | CO2020010467A2 (fr) |
| CR (1) | CR20200355A (fr) |
| IL (2) | IL302626A (fr) |
| MA (1) | MA51672A (fr) |
| MX (2) | MX2020007759A (fr) |
| PE (1) | PE20210044A1 (fr) |
| PH (1) | PH12020551059A1 (fr) |
| SG (1) | SG11202006945PA (fr) |
| WO (1) | WO2019148036A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7480048B2 (ja) | 2018-01-26 | 2024-05-09 | エグゼリクシス， インコーポレイテッド | キナーゼ依存的障害を処置するための化合物 |
| US11708367B2 (en) * | 2018-01-26 | 2023-07-25 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN111757735B (zh) * | 2018-01-26 | 2023-09-22 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| WO2021180006A1 (fr) * | 2020-03-10 | 2021-09-16 | 南京明德新药研发有限公司 | Composés de pyridine à substitution vinylique |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| CA2216796C (fr) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Derives de quinazoline |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU2004259009A1 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| CA2537812C (fr) | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | Modulateurs de c-met et procede d'utilisation |
| CA2604238C (fr) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas |
| EP3530736A3 (fr) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| EP2001880A2 (fr) | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Derives heterobicycliques de pyrazole et methodes d'utilisation |
| WO2010045095A1 (fr) * | 2008-10-14 | 2010-04-22 | Ning Xi | Composés et procédés d'utilisation |
| EP2213686A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeur et procédés d'utilisation correspondants |
| EP2214019A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeurs et leurs utilisations |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2494351B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation |
| EP2494361B2 (fr) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation |
| EP2494362B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs de tumeur de la prostate et méthodes d'utilisation |
| EP2493917B8 (fr) | 2009-10-26 | 2020-03-04 | Externautics S.P.A. | Marquers de la tumeur du sein et leur utilisation |
| EP2493916B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs associés avec des tumeurs pulmonaires et leur utilisation |
| EP2383578A1 (fr) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Marqueur de tumeur et procédés d'utilisation correspondants |
| SG187064A1 (en) | 2010-07-14 | 2013-02-28 | Zhejiang Beta Pharma Inc | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| AU2014259719B2 (en) | 2013-05-02 | 2019-10-03 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| WO2014198919A2 (fr) | 2013-06-14 | 2014-12-18 | Externautics S.P.A. | Marqueur de tumeur, anticorps monoclonaux et procédés pour les utiliser |
| EP3065772A4 (fr) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinaisons d'inhibiteurs de point de contrôle et d'agents thérapeutiques pour traiter un cancer |
| EP3134084B1 (fr) | 2014-04-25 | 2021-03-17 | Exelixis, Inc. | Procédé de traitement de l'adénocarcinome du poumon |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN107235896B (zh) | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN111511361A (zh) | 2017-12-20 | 2020-08-07 | 安杰斯制药公司 | 作为多激酶抑制剂的胺基碳酸盐及尿素化合物 |
| US11708367B2 (en) * | 2018-01-26 | 2023-07-25 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
-
2019
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 KR KR1020207024577A patent/KR20200124678A/ko not_active Application Discontinuation
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/fr active Application Filing
- 2019-01-25 CA CA3088127A patent/CA3088127A1/fr active Pending
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
- 2019-01-25 IL IL302626A patent/IL302626A/en unknown
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 EP EP19704968.7A patent/EP3743068A1/fr active Pending
- 2019-01-25 BR BR112020015199-8A patent/BR112020015199A2/pt unknown
- 2019-01-25 AU AU2019212719A patent/AU2019212719A1/en active Pending
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
-
2020
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-13 IL IL276028A patent/IL276028A/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP2023082042A/ja active Pending
- 2023-06-13 US US18/334,113 patent/US20230374024A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007759A (es) | 2020-09-24 |
| CO2020010467A2 (es) | 2020-10-30 |
| US20210040099A1 (en) | 2021-02-11 |
| US11708367B2 (en) | 2023-07-25 |
| CA3088127A1 (fr) | 2019-08-01 |
| CN112312909A (zh) | 2021-02-02 |
| JP7307733B2 (ja) | 2023-07-12 |
| JP2021511359A (ja) | 2021-05-06 |
| KR20200124678A (ko) | 2020-11-03 |
| CR20200355A (es) | 2021-02-22 |
| AU2019212719A1 (en) | 2020-08-20 |
| IL276028A (en) | 2020-08-31 |
| SG11202006945PA (en) | 2020-08-28 |
| IL302626A (en) | 2023-07-01 |
| JP2023082042A (ja) | 2023-06-13 |
| BR112020015199A2 (pt) | 2021-05-04 |
| EP3743068A1 (fr) | 2020-12-02 |
| WO2019148036A1 (fr) | 2019-08-01 |
| PH12020551059A1 (en) | 2021-05-31 |
| CL2020001930A1 (es) | 2020-12-11 |
| PE20210044A1 (es) | 2021-01-08 |
| MX2022014351A (es) | 2022-12-13 |
| US20230374024A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| MA53172A (fr) | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA52778A (fr) | Méthodes de traitement de troubles associés au récepteur s1p1 | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA51046A (fr) | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA43532A (fr) | Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
| MA47212A (fr) | Méthodes de traitement de troubles neurologiques | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
| MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
| MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv |